Dr. Garrett Dunn, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1005 W Market St Ste 7, Athens, AL 35611 Phone: 256-216-9744 Fax: 256-216-9754 |
News Archive
The U.S. Food and Drug Administration (FDA) has approved Merck & Co.'s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).
Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.
A recent study completed at the University of Eastern Finland shows that dietary polyunsaturated fatty acids may reduce the risk of coronary heart disease. The sources of polyunsaturated fatty acids include fish, vegetable oils, and nuts.
A research team led by Paul Marasco, Ph.D., of Cleveland Clinic's Lerner Research Institute, has won a $2.5 million contract from the Defense Advanced Research Projects Agency. The contract was awarded through DARPA's new Hand Proprioception and Touch Interfaces (HAPTIX) program, which aims to deliver naturalistic sensations to amputees and enable better control over their prosthetic limbs through direct connections to users' nervous systems.
Researchers in Japan who evaluated the risks and efficacy of transplanting two varieties of stem cells into mouse cochlea have concluded that both adult-derived induced pluripotent stem (iPS) cells and mouse embryonic stem (ES) cells demonstrate similar survival and neural differentiation capabilities.
› Verified 8 days ago